Fasting Serum IGFBP-1 as a Marker of Insulin Resistance in Diverse School Age Groups.
BMI – body mass index
IGFBP-1
adiposity
insulin resistance
waist circumference
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
12
2021
accepted:
14
03
2022
entrez:
19
5
2022
pubmed:
20
5
2022
medline:
21
5
2022
Statut:
epublish
Résumé
The known markers of insulin resistance in obese children are well studied. However, they require serial measurements and complicated calculations. The objective is to study IGFBP-1 and its relation with other known risk measures. The study included 98 New York City school students of diverse ethnic/racial backgrounds (57 males and 41 females), 11-15 years of age. Subjects were enrolled in a cross-sectional study, and anthropometric measures were collected. They underwent fasting intravenous glucose tolerance tests (IVGTT), and glucose, insulin, lipids, IGFBP-1, adiponectin and inflammatory markers were collected. The subjects were stratified into 3 groups based upon the BMI Z-score. Out of all the subjects, 65.3% were in the group with a BMI Z-score <1 SDS, 16.3% subjects were in the group with a BMI Z-score of 1 to 2 SDS, and 18.4% of the subjects were in the group with a BMI Z-score of more than 2 SDS. The group with a BMI Z-score of more than 2 SDS had increased waist circumference (WC), body fat, increased fasting insulin, and triglycerides (TG). This group had decreased levels of adiponectin and HDL and low IGFBP-1 as compared to the group with BMI <1 SDS. The group with a BMI Z-score of 1 to 2 SDS had a decreased level of IGFBP-1 as compared to the group with a BMI Z-score less than 1 SDS. IGFBP-1 inversely correlated with age, WC, BMI, body fat, TG, and insulin levels. IGFBP-1 positively correlated with adiponectin and HDL levels. IGFBP-1 in children can identify the presence of insulin resistance in the group with BMI 1 to 2 SDS, even before the known markers of insulin resistance such as elevated triglycerides and even before decreased HDL and adiponectin levels are identified.
Identifiants
pubmed: 35586622
doi: 10.3389/fendo.2022.840361
pmc: PMC9108162
doi:
Substances chimiques
Adiponectin
0
Biomarkers
0
IGFBP1 protein, human
0
Insulin
0
Insulin-Like Growth Factor Binding Protein 1
0
Triglycerides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
840361Informations de copyright
Copyright © 2022 Bhangoo, Gupta, Shelov, Carey, Accacha, Fennoy, Altshuler, Lowell, Rapaport, Rosenfeld, Speiser, Ten and Rosenbaum.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer EG declared a shared affiliation with the author RR to the handling editor at the time of review.
Références
Diabetologia. 2001 Mar;44(3):333-9
pubmed: 11317665
Lipids Health Dis. 2010 Dec 07;9:138
pubmed: 21134293
Am J Clin Nutr. 2018 Aug 1;108(2):388-397
pubmed: 30101328
J Biol Chem. 2000 Mar 10;275(10):7289-95
pubmed: 10702299
Obesity (Silver Spring). 2007 Sep;15(9):2217-24
pubmed: 17890489
Diabet Med. 1998 Apr;15(4):297-303
pubmed: 9585394
Mol Metab. 2019 Jan;19:86-96
pubmed: 30392760
Diabetes Care. 1999 Sep;22(9):1462-70
pubmed: 10480510
Clin Endocrinol (Oxf). 1998 Apr;48(4):487-92
pubmed: 9640416
Diabetes Care. 2008 Apr;31(4):783-8
pubmed: 18174496
J Clin Endocrinol Metab. 2008 Dec;93(12):4867-72
pubmed: 18796514
Diabetes. 1999 Sep;48(9):1686-90
pubmed: 10480595
J Clin Endocrinol Metab. 1996 Feb;81(2):860-3
pubmed: 8636318
J Clin Endocrinol Metab. 2009 Aug;94(8):3017-24
pubmed: 19470629
Diabetes. 2002 Apr;51(4):1263-70
pubmed: 11916954
Metabolism. 2019 Oct;99:119-125
pubmed: 31158368
J Clin Endocrinol Metab. 1998 Jun;83(6):1935-9
pubmed: 9626122
J Clin Endocrinol Metab. 1994 Sep;79(3):872-8
pubmed: 7521354
Diabetes. 2001 Nov;50(11):2444-50
pubmed: 11679420
J Clin Endocrinol Metab. 2004 Jan;89(1):114-20
pubmed: 14715837
Eur J Endocrinol. 1999 Mar;140(3):231-4
pubmed: 10216518
Endocrinology. 2008 Oct;149(10):4829-36
pubmed: 18566119
J Endocrinol. 2003 Dec;179(3):405-15
pubmed: 14656210
Diabetes Care. 2005 Jan;28(1):148-50
pubmed: 15616249
Pediatr Diabetes. 2016 Mar;17(2):77-86
pubmed: 25491378
Clin Endocrinol (Oxf). 2018 Jul 10;:
pubmed: 29989677
Metabolism. 2007 Oct;56(10):1412-7
pubmed: 17884454
J Clin Invest. 2006 Jul;116(7):1784-92
pubmed: 16823476
Adv Data. 2000 Jun 8;(314):1-27
pubmed: 11183293
Front Endocrinol (Lausanne). 2021 Jul 28;12:727004
pubmed: 34394011
J Biol Regul Homeost Agents. 2013 Jan-Mar;27(1):259-66
pubmed: 23489706
J Pediatr Endocrinol Metab. 2009 Apr;22(4):353-61
pubmed: 19554810
J Clin Endocrinol Metab. 2004 Nov;89(11):5469-76
pubmed: 15531499
Circulation. 2005 Apr 19;111(15):1985-91
pubmed: 15837953
Obesity (Silver Spring). 2013 Oct;21(10):2081-90
pubmed: 23596082
PLoS One. 2014 Nov 20;9(11):e113576
pubmed: 25411786
Diabetes Technol Ther. 2007 Feb;9(1):43-51
pubmed: 17316097
Int J Pediatr Obes. 2011 Aug;6(3-4):236-43
pubmed: 21198359
Mol Endocrinol. 1993 Dec;7(12):1561-8
pubmed: 7511786
N Engl J Med. 2017 Nov 23;377(21):2063-2072
pubmed: 29166236
Cell Biochem Biophys. 2007;48(2-3):73-8
pubmed: 17709876
J Clin Endocrinol Metab. 2005 Aug;90(8):4542-8
pubmed: 15914524
J Pediatr. 2016 Jan;168:212-219
pubmed: 26490124
J Clin Endocrinol Metab. 2005 Mar;90(3):1550-6
pubmed: 15613437
Am J Physiol Regul Integr Comp Physiol. 2002 Aug;283(2):R281-3
pubmed: 12121837
J Clin Endocrinol Metab. 2005 Feb;90(2):761-7
pubmed: 15546909
J Clin Endocrinol Metab. 2016 Jun;101(6):2493-501
pubmed: 27115061
Diabetes Care. 2004 Oct;27(10):2438-43
pubmed: 15451913